Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Alger Weatherbie Specialized Growth Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"The fund outperformed its benchmark in Q4 2025, buoyed by solid healthcare diagnostic and medical technology earnings, while maintaining a constructive medium-term outlook on AI, cloud, and fiscal CapEx catalysts."
In Q4 2025, the Alger Weatherbie Specialized Growth Fund (Class A shares) outperformed the Russell 2500 Growth Index. Positive performance was driven by key healthcare holdings including Natera, Acadia Pharmaceuticals, and Glaukos. Conversely, cyclical headwinds and transition-related uncertainties impacted holdings such as FirstService, AAR Corp, and Kratos Defense. The broader market was defined by widening dispersion under the surface, showing both AI-related enthusiasm and macro risks like labor softening, cautious consumer cohorts, and a government shutdown. The fund remains constructive on secular digitization, cloud computing, and AI opportunities, complemented by capital expenditure incentives from the 'One Big Beautiful Bill'.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: The fund outperformed its benchmark in Q4 2025, buoyed by solid healthcare diagnostic and medical technology earnings, while maintaining a constructive medium-term outlook on AI, c...
Growth Outlook
Market outlook remains above average conviction: The fund outperformed its benchmark in Q4 2025, buoyed by solid healthcare diagnostic and medical technology earnings, while maintaining a constructive medium-term outlook on AI, c...
Risk Appetite
Risk appetite posture is high conviction: The fund outperformed its benchmark in Q4 2025, buoyed by solid healthcare diagnostic and medical technology earnings, while maintaining a constructive medium-term outlook on AI, c...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. The fund outperformed its benchmark in Q4 2025, buoyed by solid healthcare diagnostic and medical technology earnings, while maintaining a constructive medium-term outlook on AI, c...
Forward Guidance
Forward guidance signal: The fund outperformed its benchmark in Q4 2025, buoyed by solid healthcare diagnostic and medical technology earnings, while maintaining a constructive medium-term outlook on AI, c...
Language Signal
Tone analysis indicates above average conviction language: The fund outperformed its benchmark in Q4 2025, buoyed by solid healthcare diagnostic and medical technology earnings, while maintaining a constructive medium-term outlook on AI, c...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. The fund outperformed its benchmark in Q4 2025, buoyed by solid healthcare diagnostic and medical technology earnings, while maintaining a constructive medium-term outlook on AI, c...
Opportunity Density
Opportunity density index indicates high conviction actionable entry points. The fund outperformed its benchmark in Q4 2025, buoyed by solid healthcare diagnostic and medical technology earnings, while maintaining a constructive medium-term outlook on AI, c...
Time Horizon
Investment time horizon reflects a high conviction orientation. The fund outperformed its benchmark in Q4 2025, buoyed by solid healthcare diagnostic and medical technology earnings, while maintaining a constructive medium-term outlook on AI, c...
